Mixed Adeno-Neuroendocrine Carcinoma; Case Series of Ten Patients with Review of the Literature

Balkan Med J. 2018 May 29;35(3):263-267. doi: 10.4274/balkanmedj.2017.1471. Epub 2018 Mar 19.

Abstract

Aims: Mixed adeno-neuroendocrine carcinoma is a rare entity, diagnosed with immunohistochemical studies. Literature mainly includes case reports and series which are very few. In our study, we aimed to report a case series from a tertiary hospital with demographics of the patients, detailed tumor and clinical findings and follow-up plus survival conditions.

Methods: Pathology database was explored for patients with the pathological diagnosis of ‘mixed adeno-neuroendocrine carcinoma’ and patients were identified retrospectively and evaluated in means of demographics, histopathological examination, tumor properties.

Results: Ten patients had been diagnosed with mixed adeno-neuroendocrine carcinoma in our center, diagnosed at a mean age of 64.7. Stomach was found to be the most common localization. Five patients (50%) were diagnosed as grade 3. Following surgery, median follow-up was 15 months with a median survival time of 20.6 months.

Conclusion: This case series may contribute to the literature on the pathological and clinical aspects of the mixed adenoneuroendocrine carcinoma of the gastrointestinal system.

Keywords: Digestive system; mixed adenoneuroendocrine carcinoma; neuroendocrine neoplasm; prognosis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma / diagnosis*
  • Adenocarcinoma / pathology
  • Adenocarcinoma / surgery
  • Adult
  • Biomarkers, Tumor
  • Carcinoma, Neuroendocrine / diagnosis*
  • Carcinoma, Neuroendocrine / pathology
  • Carcinoma, Neuroendocrine / surgery
  • Female
  • Gastrointestinal Neoplasms / diagnosis*
  • Gastrointestinal Neoplasms / pathology
  • Gastrointestinal Neoplasms / surgery
  • Humans
  • Male
  • Middle Aged
  • Neuroendocrine Tumors
  • Prognosis
  • Retrospective Studies
  • Stomach Neoplasms / diagnosis
  • Stomach Neoplasms / pathology
  • Survival Rate
  • Treatment Outcome

Substances

  • Biomarkers, Tumor